Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
| Publicado en: | Advances in Therapy Vol. 41; no. 9; pp. 3557 - 3569 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Sep2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=179277785&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 179277785 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0741238X 1XDX jtl: Advances in Therapy issn: 0741238X maglogo: N pubinfo: dt: Sep2024 vid: 41 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 179277785 178552783 10.1007/s12325-024-02940-8 179277785 ppf: 3557 ppct: 12 formats: tig: atl: Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study. aug: au: Cao, Guoying Yang, Haijing Wang, Jingjing Ishida, Masahiro Thoma, Christian Haeufel, Thomas Bossert, Sebastian Zhang, Jing affil: Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Jingan District, 200040, Shanghai, China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|